Table 2.
Typical basis for selection of administered activities and routine dosimetry performed.
| Disease to be Treated | Molecular Radiotherapy Radiopharmaceutical | Dosimetry Notes |
|---|---|---|
| Differentiated thyroid cancer | 131I sodium iodide | Routinely fixed administered activity. Two means of personalised dosimetry: the lesion/remnant disease-based method; and the bone marrow dose method |
| Neuroblastoma | 131I mIBG | Administered activity scaled to weight or body surface area. Can be tailored to individual patients based on whole-body absorbed dose. |
| Neuroendocrine cancers |
177Lu DOTATATE 90Y DOTATOC |
Routinely fixed administered activity. 177Lu DOTATATE dosimetry can be calculated using the gamma emissions to obtain post therapy planar images; 90Y DOTATOC not routinely possible. |
| 89Sr strontium chloride | Fixed administered activity. Dosimetry not routinely performed | |
| Metastatic prostate cancer |
153Sm lexidronam 186Re etidronate 223Ra radium dichloride |
153Sm lexidronam weight-based administered activity; 186Re etidronate fixed administered activity; no more detailed dosimetry routinely performed. 223Ra photons allow for post-treatment imaging. Low-dose pre-treatment administration also allow potential for greater dosimetric accuracy. |
| 177Lu PMSA | 68Ga PSMA diagnostic imaging used for pre-therapeutic dosimetric calculation; 177Lu gamma emission allows dosimetric calculation for subsequent therapies. | |
| Acute leukaemia | 90Y anti-CD66 monoclonal antibody | 111In labeled anti-CD66 monoclonal antibody single photon emission computed tomography used for dosimetric calculation prior to therapy to ensure bone marrow limit not exceeded. |